Mitsubishi Tanabe Pharma Pension Fund

Chairman Tokuno Shigenari holds the senior governance role as 理事長, while Managing Director and CIO Hiroki Masuoka is responsible for asset allocation and investment strategy execution. The fund operates under the oversight of its sponsor's corporate governance framework, which shifted in 2025 when Bain Capital acquired Mitsubishi Tanabe Pharma Corporation through K.K. BCJ-94.

Publicly available information does not clarify whether the fund engages in direct co-investments or operates solely through fund commitments. Most Japanese corporate pension funds of this scale delegate investment management to external institutions via separate account mandates or commingled fund vehicles, with limited direct deal activity. The fund's manager selection process is governed by Japanese fiduciary regulations under the Financial Instruments and Exchange Act.

The Mitsubishi Tanabe Pharma Pension Fund is specific to employees of Mitsubishi Tanabe Pharma Corporation and is not pooled with other Mitsubishi keiretsu entities. Each major Mitsubishi group company — including Mitsubishi Corporation, Mitsubishi Heavy Industries, and Mitsubishi UFJ Financial Group — maintains its own separate pension arrangements. The Tanabe Pharma fund operates independently with its own board, CIO, and investment policy.